Personalized Management of Chemotherapy‐Induced Peripheral Neuropathy Based on a Patient Reported Outcome: CALGB 40502 (Alliance)

Chemotherapy‐induced peripheral neuropathy (henceforth, neuropathy) is often dose limiting and is generally managed by empirical dose modifications. We aimed to (1) identify an early time point that is predictive of future neuropathy using a patient‐reported outcome and (2) propose a dose‐adjustment...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Journal of clinical pharmacology 2020-04, Vol.60 (4), p.444-452
Hauptverfasser:	Sharma, Manish R., Mehrotra, Shailly, Gray, Elizabeth, Wu, Kehua, Barry, William T., Hudis, Clifford, Winer, Eric P., Lyss, Alan P., Toppmeyer, Deborah L., Moreno‐Aspitia, Alvaro, Lad, Thomas E., Velasco, Mario, Overmoyer, Beth, Rugo, Hope S., Ratain, Mark J., Gobburu, Jogarao V.
Format:	Artikel
Sprache:	eng
Schlagworte:	Albumin Algorithms Breast cancer Chemotherapy Dosage Metastases modeling and simulation Nanoparticles neuropathy Paclitaxel Patients Peripheral neuropathy personalized
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!